DGAP-News: After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test
- 58
DGAP-News: Digital Diagnostics AG
/ Key word(s): Miscellaneous
Mainz, Germany--(Newsfile Corp. - May 29, 2020) - At the high-security laboratory of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, the revolutionary Cantisense™ technology of the German health technology company Digital Diagnostics AG was used for the first time to successfully detect SARS-CoV-2 viruses in high measuring accuracy in test liquids. Figure 1: Point-of-care test kit: sensor hub, biosensor, mobile device With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the numerous sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. (prototype/copyright: Digital Diagnostics AG) To view an enhanced version of Figure 1, please visit: In contrast to PCR testing, the new test provides a clear electronic "YES" or "NO" information within a few minutes, saving precious time in the diagnosis. What's more, the Digid Cantisense™ SARS-CoV-2 Test directly detects the presence of the virus while other rapid tests only recognize antibodies. Konstantin Kloppstech, CTO at Digital Diagnostics, says: "Recent test series at the HZI high-security laboratory have shown that SARS-CoV-2 viruses can be detected directly using our Cantisense technology and without the need for PCR or further sample processing. This is a scientific breakthrough. We have coated cantilevers with a capture layer of highly specific monoclonal antibodies, which can reliably bind SARS-CO-2 viruses in the test fluid." Constantin von Gersdorff, CEO of Digital Diagnostics, said: "The next step will be to initiate clinical studies with patient samples. To this end, we have already established international collaborations with leading hospitals." With Digid's test kit, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. Due to its measurement speed and the highly reliable results, the test is particularly suitable to support the containment of the current SARS-CoV-2 pandemic. The test offers the possibility of simple and rapid testing of patients and medical staff as an alternative to laboratory tests and enables reliable identification of infected persons within minutes. The possible areas of application therefore also include screening for access control at airports and railway stations, hospitals and specially protected areas (such as retirement homes) as well as for companies who want to ensure that their production runs smoothly and safely. Digital Diagnostics has applied for approval of the Digid Cantisense™ SARS-CoV-2 Test by the US Food and Drug Administration (FDA). Digid aims to provide millions of units by July 2020. A further scaling of capacities is planned in the short term. The experts at Digital Diagnostics are also working at full speed to further develop the technology and to adapt the point-of-care testing procedure for use by consumers at home. Press contact Related Images point-of-care-test-kit-sensor-hub.jpg Related Links To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56911 Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/56911News Source: Newsfile
30.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Digital Diagnostics AG |
United States | |
EQS News ID: | 1059625 |
End of News | DGAP News Service |
|
1059625 30.05.2020
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.
- What's the Buzz about 4/20? Cannabis and Mental Health Canada celebrates and reflects on the recent Legislative Review of the Cannabis Act
- Trupanion, Inc. Announces First Quarter 2024 Earnings Release and Conference Call
- EQS-News: Mangrove LuxCo III S.à r.l.: Invitation Q4 2023 Investor Conference Call
- Alkami to Announce First Quarter 2024 Financial Results
- Rodedawg Intl. Ind, Inc. (OTC: RWGI) Provides 2nd Quarter Company Milestone Updates for April 2024
- Acme United Reports 39% Increase in Earnings Per Share for First Quarter of 2024